Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best strong buy growth stocks to buy now. On August 28, Teva ...

Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

Israeli drugmaker Teva Pharmaceutical Industries has announced US Food and Drug Administration (FDA) approval and launch of a ...

Teva is releasing a generic version of Novo Nordisk’s Saxenda, a liraglutide injection. Liraglutide injection is indicated for adults with obesity or overweight who also have weight related medical ...

Teva Pharmaceuticals announced in late August 2025 that it received FDA approval and commenced the U.S. launch of its generic version of Saxenda® (liraglutide injection), which had annual sales of ...

Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the ...

Saxenda Approved for Weight Management New Phase 3a data indicates that overweight or obese adults with comorbidities had greater improvements in weight loss, fasting plasma glucose (FPG ...

Saxenda, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated as an adjunct to a reduced- calorie diet and increased physical activity for chronic weight management in adults with ...

Novo Nordisk A/S NVO announced the presentation of new data from the phase IIIa SCALE Obesity and Prediabetes study on Saxenda at The Endocrine.